Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

  • CEO: Gordon Sanghera
  • Website: www.nanoporetech.com
  • Ticker symbol: Privately held
  • Headquarters: Oxford, UK
  • Number of employees: 250+

In PLOS this week: population genetics of region with high Burkitt lymphoma rates, analysis of Brazilian Chikungunya virus strains, and more.

The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.

Three long-read assemblies — two from PacBio data alone and one from Oxford Nanopore and Illumina data — had considerably more indel errors in genes than short-read assemblies.

Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.

Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.

In Science this week: metagenomic nanopore sequencing of Lassa fever outbreak, and more.

New Pore and More

At a user meeting, Oxford Nanopore gave an update on what it has been working on.

Users expressed concern that Illumina would have an even tighter grip on the sequencing market but are optimistic that it would spur development of PacBio's technology.

Pages

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.